Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphocytic Leukemia Therapy
Reports on acute lymphocytic leukemia therapy findings from Soochow University, Department of Hematology provide new insights
March 9th, 2008
New research, 'CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases,' is the subject of a report. According to recent research from Suzhou, People's Republic of China, "Patients with either relapsed or refractory T-cell acute lymphocytic leukemia (T-ALL) are candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Achieving complete remission (CR) in these patients is difficult but crucial for the success of allo-HSCT." "In this study, we examined 6 relapsed or refractory T-ALL patients. In the patient group, 4 were male and 2 were female, with ages ranging from...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-09)
|
